Cargando…
Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden
BACKGROUND: Prolonged, high-dose corticosteroid treatment for systemic lupus erythematosus (SLE) is associated with substantial health care costs, health care resource utilization (HCRU), and adverse events (AEs). OBJECTIVE: To compare all-cause health care costs, HCRU, and oral corticosteroid (OCS)...
Autores principales: | Huang, Shirley P, DerSarkissian, Maral, Gu, Yuqian M, Duh, Mei Sheng, Wang, Min-Jung, Benson, John, Vu, Jensen, Averell, Carlyne, Bell, Christopher F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387938/ https://www.ncbi.nlm.nih.gov/pubmed/36989451 http://dx.doi.org/10.18553/jmcp.2023.29.4.365 |
Ejemplares similares
-
Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
por: DerSarkissian, Maral, et al.
Publicado: (2023) -
A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA
por: Bell, Christopher F., et al.
Publicado: (2022) -
Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study
por: Huang, Shirley P., et al.
Publicado: (2023) -
The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States
por: Bell, Christopher F, et al.
Publicado: (2022) -
Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis
por: Bell, Christopher F, et al.
Publicado: (2023)